Status:
TERMINATED
Evaluation of 2 Doses of Intravenous Droperidol in the Prevention of Postoperative Nausea
Lead Sponsor:
University Hospital, Bordeaux
Collaborating Sponsors:
Kyowa Kirin Co., Ltd.
Conditions:
Nausea
Vomiting
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Brief Summary
In this prospective, randomised, placebo-controlled study, the researchers determined whether 0.625 mg or 2.5 mg of IV droperidol given 30 min before emergence from general anaesthesia reduces the inc...
Detailed Description
* Principal Objective : Our study examined one main question: Are there difference in efficacy between droperidol IV 0.625 mg or 2.5 mg for the treatment or prophylaxis of PONV to surgical patient und...
Eligibility Criteria
Inclusion
- Female
- More than 18 years old
- Patients scheduled for thyroid surgery
- Simplified Apfel score ≥ 2
- ASA score : 1-2
- Informed consent obtained from the patient
- Women able to procreate must have a reliable contraceptive method
Exclusion
- Age \< 18 years old
- Male
- Obesity
- Has a severe depressive syndrome
- Pregnancy women
- Trouble with cardiac rate
- Alcoholism
- Contra-indication for Droperidol prescription
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT00445055
Start Date
April 1 2007
End Date
April 1 2009
Last Update
December 13 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Département d'Anesthésie-Réanimation II ; Groupe Hospitalier Sud, CHU de Bordeaux
Pessac, France, 33604